• Langley Road, Brighton, MA
  • 416-402-8274

NIH Licensing Opportunity: Breakthrough Cancer Drug Delivery Platform with Direct Active Entry into the Lymphatic System


  • Start Date:September 10, 2020
  • End Date: September 10, 2020
  • Start Time:11:00 EST
  • End Time:12:00 EST
  • Location:
  • Email:
  • Register


  • Start Date:September 10, 2020
  • End Date: September 10, 2020
  • Start Time:11:00 EST
  • End Time:12:00 EST


This webinar already occurred on September 10, 2020 but a recording can be watched below:

Signature Square OMSIH logo

One Million Solutions in Health™ has established a one-of-a-kind partnership with the United States’ National Institutes of Health Office of Technology Transfer (NIH-OTT) and the National Cancer Institute Technology Transfer Center (NCI-TTC) to increase awareness and understanding of NIH technologies by potential partners in the life science and healthcare industries.

This provides you with a front-row seat to hear about new technology and science from various scientists at the NIH. This is also your opportunity to participate in our proprietary Signature Square™ process, where end-users can evaluate the technology, ask questions and provide feedback directly to the scientist.

Novel Therapeutic Delivery Platform

This webinar demonstrated how this Polylysine Succinate (PLS) platform is superior to liposome and micellar drug delivery systems. For new therapeutics, use less drug, with less side effects and higher efficacy. For current therapeutics, this could extend your patent life. This PLS platform has the ability to replace liposome and micellar systems, and become the new Gold Standard.

This technology is directed to a polylysinesuccinate (PLS) based polymeric drug delivery platform that delivers a therapeutic cargo (e.g., small molecule drugs, therapeutic peptides, and vaccines) to the lymphatic system and myeloid/antigen presenting cell (APC) sub-populations. The PLS based delivery platform specifically targets scavenger receptor A1 (SR-A1), a receptor highly expressed in macrophages, monocytes, mast cells, dendritic cells (myeloid lineages), and endothelial cells. Unlike currently available therapeutics that target the lymphatic system through passive diffusion through porous vasculature, this novel PLS delivery platform selectively targets the lymphatic system through SR-A1 mediated transcytosis. The PLS delivery platform has superior stability and release characteristics, compared to currently available therapeutics targeting the lymphatic system, releasing the therapeutic payload in a manner that results in a superior therapeutic effect.

This is an opportunity to LICENSE THIS TECHNOLOGY, or participate in further collaborative work to enhance its development.

The Signature Square process is part of our Consortium infrastructure. Current member companies in the Technology Evaluation Consortium and SafeTEC include organizations like AstraZeneca, AbbVie, Amgen and Allergan, along with many others, including scientists, clinicians and investors in organizations around the world who help to evaluate this technology.

This is your opportunity to ask questions and provide feedback directly to the scientists by taking part in this Signature Square program.

Stephan T. Stern, Ph.D., DABT
Laboratory Co-Director, Director of Research & Development
Nanotechnology Characterization Laboratory
Frederick National Laboratory for Cancer Research

Dawn Van Dam
Executive Director & CEO
One Million Solutions in Health™